Publikationen in Zusammenarbeit mit Forschern von Fundación Hospital Alcorcón (23)

2023

  1. Shared Decision-Making in Allergen Immunotherapy (AIT) Options Using a Questionnaire for Respiratory Allergic Patients: A Delphi Consensus Study

    Patient Preference and Adherence, Vol. 17, pp. 1771-1782

2021

  1. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  3. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial

    European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264

2017

  1. Clinical and epidemiological differences between men and women with systemic sclerosis: A study in a Spanish systemic sclerosis cohort and literature review

    Clinical and Experimental Rheumatology, Vol. 35, pp. S89-S97

  2. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. Factores asociados a estancias cortas en los pacientes ingresados por insuficiencia cardiaca aguda

    Emergencias, Vol. 28, Núm. 6, pp. 366-374

  3. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

  4. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

  5. Tiempo de estancia prolongado en los pacientes ingresados por insuficiencia cardiaca aguda

    Gaceta Sanitaria, Vol. 30, Núm. 3, pp. 191-200

2014

  1. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: An Allergists' Consensus

    Clinical and Translational Allergy, Vol. 4, Núm. 1

  2. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  3. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

2013

  1. Dislipidemia en población diabé tica tratada con estatinas. Resultados del Dyslipidemia International Study en España

    Medicina Clinica, Vol. 141, Núm. 10, pp. 430-436

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

  2. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire

    Respiratory Research, Vol. 13

2011

  1. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain study

    Revista Espanola de Cardiologia, Vol. 64, Núm. 4, pp. 286-294

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941